|
Media Releases |
Financial Reports |
Presen-tations |
|
10/09/2007
|
|
|
|
| Lonza Introduces Clonetics® Rat Cardiac Myocytes. |
Basel, 09.10.2007 – Lonza announces the availability of Clonetics® Neonatal Rat Cardiac Myocytes for use in cardiovascular and toxicological research. These cryopreserved cells offer you functional, beating cardiac myocytes upon thaw, at your convenience. Cardiac myocytes provide research laboratories with ready to use primary cells for studies in areas such as cell contraction and physiology, ion channel flux, cardiac lipid metabolism and lipotoxicity, cardiac injury and apoptosis, inflammation, hypertension, and cytotoxicity.
The Clonetics® Neonatal Rat Cardiac Myocytes are cryopreserved primary ventricular myocytes isolated from Sprague-Dawley rats at P1-3. These cells are ≥ 85% pure after thaw with ≥ 80% viability. Cells stain positive for actinin, and are electrophysiologically active as demonstrated by in vitro beating after 24 hours in culture. Cells are tested and guaranteed to be mycoplasma and bacteria free.
Using a Multi Electrode Array device, these cryopreserved cells have recorded comparable electrical activity to fresh cells, and demonstrated appropriate responses to cardioactive substances.
“Avoid the hassle of obtaining rats and performing your own dissections and isolations. Cryopreserved cells offer the convenience and flexibility of using the cells when your experiments are ready for them. Cardiovascular research funding has been rapidly increasing over the past decade, and these new rat cardiac myocytes provide the in vitro tools needed to help expedite these research projects and make them more cost effective,” states Shawn Cavanagh, Head of Lonza Bioscience.
For more information on this product or to place an order, please visit www.lonzabioscience.com/prod.ratcmc. For technical service please call +1 800-638-8174.
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2006, Lonza had sales of CHF 2.91 billion. Further information can be found at www.lonza.com.
For further Information:
Head Corporate Communicationsza
Janet White
Tel +41 61 316 8566
Fax +41 61 316 9566
janet.white@lonza.com
Media Relations
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com
Investor Relations
Alexandre Pasini
Tel +41 61 316 8835
Fax +41 61 316 9835
alexandre.pasini@lonza.com
|
|
|
